Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Med J Malaysia ; 74(6): 472-476, 2019 12.
Article in English | MEDLINE | ID: mdl-31929471

ABSTRACT

INTRODUCTION: Melioidosis is caused by Burkholderia pseudomallei, a gram-negative aerobic bacillus, found in the soil and surface water. Treating melioidosis has been a challenge in district hospitals due to high usage of broad spectrum antibiotics and prolonged hospitalisation. This study is to review the patients' demography, clinical presentations and microbiological data. METHODS: A 5-year retrospective study was carried out on patients admitted with culture positive for melioidosis from year 2013 to 2017 in Hospital Teluk Intan, Perak. RESULTS: There were a total of 46 confirmed cases of melioidosis. Majority of the patients were working in the agricultural and farming (28.6%), and factories (25.7%). Thirty-one patients had diabetes mellitus (71.1%). Presentations of patients with melioidosis included pneumonia (54.3%), skin and soft tissue infection (19.6%), deep abscesses (15.2%) and bone and joint infections (13%). An average of 5.8 days was needed to confirm the diagnosis of melioidosis via positive culture. However, only 39.4% of these patients were started on ceftazidime or carbapenem as the empirical therapy. The intensive care unit (ICU) admission rate for melioidosis was 46% and the mortality rate was 52%. Our microbial cultures showed good sensitivity towards cotrimoxazole (97.1%), ceftazidime (100%) and carbapenem (100%). CONCLUSION: Melioidosis carries high mortality rate, especially with lung involvement and bacteremia. Physicians should have high clinical suspicion for melioidosis cases to give appropriate antimelioidosis therapy early.


Subject(s)
Bacteremia/drug therapy , Ceftazidime/therapeutic use , Hospitals, District/statistics & numerical data , Melioidosis/drug therapy , Adult , Anti-Bacterial Agents/therapeutic use , Bacteremia/epidemiology , Bacteremia/microbiology , Burkholderia pseudomallei/isolation & purification , Female , Follow-Up Studies , Hospitalization/trends , Humans , Incidence , Malaysia/epidemiology , Male , Melioidosis/epidemiology , Melioidosis/microbiology , Middle Aged , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Young Adult
2.
Br J Anaesth ; 120(5): 1056-1065, 2018 May.
Article in English | MEDLINE | ID: mdl-29661383

ABSTRACT

BACKGROUND: Atomised intranasal dexmedetomidine administration is an attractive option when sedation is required for paediatric diagnostic procedures, as vascular access is not required. The risk of haemodynamic instability caused by dexmedetomidine necessitates better understanding of its pharmacokinetics in young children. To date, intranasal dexmedetomidine pharmacokinetics has only been studied in adults. METHODS: Eighteen paediatric patients received dexmedetomidine 1 or 2 µg kg-1 intranasally or 1 µg kg-1 i.v. Plasma concentrations were determined by liquid chromatography/mass spectrometry. Non-compartmental analysis provided estimates of Cmax and Tmax. Volume of distribution, clearance, and bioavailability were estimated by simultaneous population PK analysis of data after intranasal and i.v. administration. Dexmedetomidine plasma concentration-time profiles were evaluated by simulation for intranasal and i.v. administration. RESULTS: An average peak plasma concentration of 199 pg ml-1 was achieved 46 min after 1 µg kg-1 dosing and 355 pg ml-1 was achieved 47 min after 2 µg kg-1 dosing. A two-compartment pharmacokinetic model, with allometrically scaled parameters, adequately described the data. Typical bioavailability was 83.8% (95% confidence interval 69.5-98.1%). CONCLUSION: Mean arterial plasma concentrations of dexmedetomidine in infants and toddlers approached 100 pg ml-1, the low end reported for sedative efficacy, within 20 min of an atomised intranasal administration of 1 µg kg-1. Doubling the dose to 2 µg kg-1 reached this plasma concentration within 10 min and achieved almost twice the peak concentration. Peak plasma concentrations with both doses were reached within 47 min of intranasal administration, with an overall bioavailability of 84%.


Subject(s)
Anesthesia/methods , Dexmedetomidine/administration & dosage , Dexmedetomidine/pharmacokinetics , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/pharmacokinetics , Administration, Intranasal , Child, Preschool , Dexmedetomidine/blood , Dose-Response Relationship, Drug , Female , Humans , Hypnotics and Sedatives/blood , Infant , Male , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...